These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 25039428)

  • 1. Peripheral and cognitive signs: delineating the significance of impaired catecholamine metabolism in Parkinson's disease progression.
    Salvatore MF; Disbrow EA; Emborg ME
    J Neurochem; 2014 Oct; 131(2):129-33. PubMed ID: 25039428
    [No Abstract]   [Full Text] [Related]  

  • 2. Biomarkers of cognitive decline in Parkinson's disease.
    Lin CH; Wu RM
    Parkinsonism Relat Disord; 2015 May; 21(5):431-43. PubMed ID: 25737398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive impairment in Parkinson's disease.
    Montine TJ
    Brain Pathol; 2010 May; 20(3):632. PubMed ID: 20522087
    [No Abstract]   [Full Text] [Related]  

  • 4. [Catecholamine metabolism in Parkinson's disease with depression].
    Selikhova MV; Kogan BM; Ustinova IL
    Zh Nevrol Psikhiatr Im S S Korsakova; 2003; 103(1):39-42. PubMed ID: 12616737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive issues in Parkinson's disease.
    Elmer L
    Neurol Clin; 2004 Oct; 22(3 Suppl):S91-S106. PubMed ID: 15501368
    [No Abstract]   [Full Text] [Related]  

  • 6. Neuroimaging studies of different cognitive profiles in Parkinson's disease.
    Monchi O; Degroot C; Mejia-Constain B; Bruneau MA
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S77-9. PubMed ID: 22166462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroimaging biomarkers for Parkinson disease: facts and fantasy.
    Perlmutter JS; Norris SA
    Ann Neurol; 2014 Dec; 76(6):769-83. PubMed ID: 25363872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Nonmotor signs of Parkinson's disease].
    Tavadian ZD; Bakunts GO
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(5):81-5. PubMed ID: 25035883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profile of cognitive impairment in Parkinson's disease.
    Watson GS; Leverenz JB
    Brain Pathol; 2010 May; 20(3):640-5. PubMed ID: 20522089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The meaning of a "hippo" response on the Montreal Cognitive Assessment in Parkinson's disease.
    Armstrong MJ; Duff-Canning S; Tang-Wai DF; Fox S; Zadikoff C; Kennedy N; Gill D; Eslinger PJ; Mapstone M; Chou KL; Persad C; Litvan I; Mast BT; Marras C
    Parkinsonism Relat Disord; 2013 Apr; 19(4):463-5. PubMed ID: 23036511
    [No Abstract]   [Full Text] [Related]  

  • 11. Dementia and cognitive impairment in Parkinson's disease.
    Girotti F; Soliveri P; Carella F; Piccolo I; Caffarra P; Musicco M; Caraceni T
    J Neurol Neurosurg Psychiatry; 1988 Dec; 51(12):1498-502. PubMed ID: 3221216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. French consensus procedure for assessing cognitive function in Parkinson's disease.
    Dujardin K; Auzou N; Lhommée E; Czernecki V; Dubois B; Fradet A; Maltete D; Meyer M; Pineau F; Schmitt E; Sellal F; Tison F; Vidal T; Azulay JP; Welter ML; Corvol JC; Durif F; Rascol O;
    Rev Neurol (Paris); 2016 Nov; 172(11):696-702. PubMed ID: 27318613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Abnormalities of catecholamine metabolism in Parkinson's disease (author's transl)].
    Nagatsu T
    Tanpakushitsu Kakusan Koso; 1981 Aug; 26(11):1781-8. PubMed ID: 6117927
    [No Abstract]   [Full Text] [Related]  

  • 14. Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment.
    Svenningsson P; Westman E; Ballard C; Aarsland D
    Lancet Neurol; 2012 Aug; 11(8):697-707. PubMed ID: 22814541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive impairment.
    Muayqil T
    Neurosciences (Riyadh); 2016 Jan; 21(1):81-3. PubMed ID: 27224973
    [No Abstract]   [Full Text] [Related]  

  • 16. Apathy in Parkinson's disease.
    Pluck GC; Brown RG
    J Neurol Neurosurg Psychiatry; 2002 Dec; 73(6):636-42. PubMed ID: 12438462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What can biomarkers tell us about cognition in Parkinson's disease?
    Mollenhauer B; Rochester L; Chen-Plotkin A; Brooks D
    Mov Disord; 2014 Apr; 29(5):622-33. PubMed ID: 24757111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resting-state fMRI sheds light on neural substrates of cognitive decline in Parkinson disease.
    Shinotoh H; Tessitore A
    Neurology; 2014 Nov; 83(22):2000-1. PubMed ID: 25355820
    [No Abstract]   [Full Text] [Related]  

  • 19. Cognitive impairment and dementia in Parkinson's disease: a controlled study.
    Boyd JL; Cruickshank CA; Kenn CW; Madeley P; Mindham RH; Oswald AG; Smith RJ; Spokes EG
    Psychol Med; 1991 Nov; 21(4):911-21. PubMed ID: 1780404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metric properties of the mini-mental Parkinson and SCOPA-COG scales for rating cognitive deterioration in Parkinson's disease.
    Serrano-Dueñas M; Calero B; Serrano S; Serrano M; Coronel P
    Mov Disord; 2010 Nov; 25(15):2555-62. PubMed ID: 20824734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.